2seventy bio, Inc. (TSVT)
NASDAQ: TSVT · IEX Real-Time Price · USD
4.205
-0.085 (-1.98%)
Apr 26, 2024, 12:39 PM EDT - Market open
2seventy bio Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for 2seventy bio stock have an average target of 10.6, with a low estimate of 5.00 and a high estimate of 18. The average target predicts an increase of 152.08% from the current stock price of 4.21.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for 2seventy bio stock from 7 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 1 | 1 | 1 | 1 |
| Hold | 5 | 5 | 5 | 5 | 5 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy Maintains $9 → $12 | Strong Buy | Maintains | $9 → $12 | +185.37% | Apr 8, 2024 |
| Wedbush | Wedbush | Hold Reiterates $5 | Hold | Reiterates | $5 | +18.91% | Mar 18, 2024 |
| Leerink Partners | Leerink Partners | Hold → Buy Upgrades $5 → $18 | Hold → Buy | Upgrades | $5 → $18 | +328.06% | Jan 31, 2024 |
| TD Cowen | TD Cowen | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Jan 31, 2024 |
| Wedbush | Wedbush | Buy → Hold Downgrades $2 | Buy → Hold | Downgrades | $2 | -52.44% | Nov 20, 2023 |
Financial Forecast
Revenue This Year
84.42M
from 100.39M
Decreased by -15.90%
Revenue Next Year
104.31M
from 84.42M
Increased by 23.56%
EPS This Year
-1.91
from -4.42
EPS Next Year
-0.68
from -1.91
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 136.8M | 160.8M | 222.1M | 140.9M | 188.5M |
| Avg | 84.4M | 104.3M | 111.9M | 126.4M | 183.1M |
| Low | 46.2M | 56.5M | 62.3M | 111.4M | 175.9M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 36.3% | 90.5% | 112.9% | 25.9% | 49.1% |
| Avg | -15.9% | 23.6% | 7.3% | 12.9% | 44.9% |
| Low | -54.0% | -33.1% | -40.3% | -0.5% | 39.2% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | -0.09 | 1.46 | 0.87 | -0.08 |
| Avg | -1.91 | -0.68 | -0.33 | -0.08 |
| Low | -3.21 | -1.56 | -1.33 | -0.08 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | - | - | - | - |
| Avg | - | - | - | - |
| Low | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.